RecruitingPhase 3NCT07548853
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis
An Open-label, Single-arm Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis
Sponsor
Taisho Pharmaceutical Co., Ltd.
Enrollment
30 participants
Start Date
May 13, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on peritoneal dialysis
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called 'TS-172 20~60 mg/day for people with hyperphosphatemia patients on peritoneal dialysis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG'TS-172 20~60 mg/day
oral administration of TS-172 20\~60 mg/day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07548853